Mazdutide
Also known as: LY3305677 · IBI362
A dual GLP-1/glucagon receptor agonist demonstrating significant weight loss and metabolic improvements, with a unique glucagon component for enhanced energy expenditure.
Overview
Mazdutide is a dual-acting peptide that agonizes both GLP-1 and glucagon receptors, developed by Eli Lilly (licensed to Innovent Biologics for China). Like retatrutide but without the GIP component, mazdutide combines appetite suppression via GLP-1 receptor activation with increased energy expenditure via glucagon receptor activation. The glucagon component stimulates hepatic fat oxidation, increases thermogenesis, and promotes liver fat reduction — addressing the metabolic side of obesity beyond just appetite control. In Phase 2 clinical trials, mazdutide demonstrated dose-dependent weight loss of up to 11.7% at 24 weeks, along with significant improvements in glycemic control and liver fat reduction.
It represents an important addition to the growing arsenal of incretin-based therapies for obesity and metabolic disease.
Mechanism of Action
Dual agonist of GLP-1 receptor (appetite suppression, gastric emptying delay, insulin secretion) and glucagon receptor (hepatic fat oxidation, thermogenesis, energy expenditure). The combination provides complementary metabolic effects — reducing caloric intake while simultaneously increasing caloric expenditure.
Key Benefits
Potential Side Effects
Common Stacks
This peptide is commonly combined with the following compounds for synergistic effects:
Known Interactions
The following interactions have been documented for Mazdutide. Always consult a healthcare professional before combining compounds.
Contraindicated (1)
Mazdutide is a dual GLP-1/glucagon agonist. Combining with semaglutide creates dangerous GLP-1 receptor overlap.
Scientific References
Quick Reference
Typical Dose
3mg-6mg
Frequency
1x daily
Route
Subcutaneous injection
Half-Life
~5-7 days (supports weekly dosing)
Cycle Length
1-2x weekly (split dose); as long as needed
FDA Status
Investigational — Phase 3 clinical trials ongoing. Approved in China for type 2 diabetes (2024). Not yet FDA approved in the US.
Need to calculate dosing?
Use our reconstitution calculator to determine exact syringe measurements.
Open CalculatorThis information is for educational purposes only. Consult a qualified healthcare professional before using any peptide. Dosing information reflects commonly reported protocols and may not be appropriate for everyone.
Related Peptides in Fat Loss & Metabolic
Semaglutide
An FDA-approved GLP-1 receptor agonist that has revolutionized weight management, producing average weight loss of 15-17% of body weight in clinical trials.
Read moreTirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that has demonstrated the most potent weight loss results of any pharmaceutical agent, averaging 20-26% body weight reduction.
Read moreAOD-9604
A modified fragment of human growth hormone (amino acids 176-191) that retains the fat-burning properties of HGH without its growth-promoting or diabetogenic effects.
Read more